Astegolimab for COPD (ARNASA Trial)

"According to the selection criteria, participants must be between 40 and 80 years old. 35 studies are available for those under 18 while 469 studies target individuals above 65."

"The safety of Astegolimab SC Q4W was rated a 3 due to the accumulated evidence from Phase 3 trials, verifying its efficacy and demonstrating that it is safe."

"Indeed, information found on clinicaltrials.gov confirms that this research is currently looking for participants. It was first published around December 30th 2022 and the most recent update occured a few days later on December 20th 2022. This experiment requires 1290 patients to be recruited from one medical centre."

"Affirmative, the research listed on clinicaltrials.gov reveals that this scientific study is at present seeking volunteers. It was first posted in December 30th 2022 and has been most recently revised on December 20th 2022. The trial seeks to recruit 1290 individuals from a single site."

"This medical trial requires 1290 volunteers aged 40 to 80 with chronic obstructive airway disease. Furthermore, the enrolment criteria include: having a COPD diagnosis for one year or longer; 20-80% post-bronchodilator FEV1 of predicted value at screening; optimised maintenance therapy such as ICS plus LABA, LAMA plus LABA, and ICS plus LAMA plus LABA for twelve months prior to screening; mMRC score ≥2 ; history of smoking 10 pack-years or more; chest X-ray within 6 months before screening confirming absence of other lung diseases besides COPD;"